Paramita M. Ghosh, Ph.D. for UC Davis Health

Paramita M. Ghosh, Ph.D.

Paramita M. Ghosh, Ph.D.

Professor

Reviews

Specialties

Genitourinary Cancers

Department

Urologic Surgery

Locations and Contact

Oak Park Research Center Building


2700 Stockton Blvd. Room 1132
Sacramento, CA 95817

Get Directions

Additional Numbers

Clinic Fax

916-734-8904

Clinic Referral Phone

916-734-7805

Physician Referrals

800-4-UCDAVIS (800-482-3284)

Research/Academic Interests

Dr. Ghosh’s research focuses on elucidating the mechanisms of prostate and bladder cancer progression, especially through understanding the signal transduction pathways involved. She also has interest in developing new targets for therapy and the re-purposing of drugs for novel uses.

Division

Urology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Undergraduate School

B.Sc., Physics, Jadavpur University, Calcutta, India 1987

Other School

M.Sc., Biophysics, Jadavpur University, Calcutta, India 1989

Other School

Ph.D., Biophysics, Rensselaer Polytechnic Institute, Troy NY 1994

Fellowship

Cellular and Structural Biology, University of Texas Health Science Center, San Antonio TX 1994

Fellowship

Pathology, University of Texas Health Science Center, San Antonio TX 1996-2000

"Exceptional Women in Endocrine Cancer” profile, Endocrine Related Cancers, 2016

Scientist Selected to Join Global Task Force focused on Cancer Causing Potential of Chemicals (Getting to know Cancer), 2013

Travel Award, 6th International Symposium on Hormonal Oncogenesis, Tokyo, Japan, 2010

California Coalition to Cure Prostate Cancer Award, Prostate Cancer Foundation, Santa Monica CA, 2007

Vasilatis DM, Lucchesi CA, Ghosh PM. Molecular Similarities and Differences between Canine Prostate Cancer and Human Prostate Cancer Variants. Biomedicines. 2023;11(4):1100. doi:10.3390/biomedicines11041100.

Katleba KD, Tsamouri MM, Jathal M, Baek HB, Armenta RB, Tepper CG, Cortopassi G, Ghosh PM, Mudryj M. Androgen receptor-dependent regulation of metabolism in high grade bladder cancer cells. Sci Rep. 2023 Jan 31;13(1):1762. doi:10.1038/s41598-023-28692-z. PMID:36720985.

Ning S, Zhao J, Lombard AP, D'Abronzo LS, Leslie AR, Sharifi M, Lou W, Liu C, Yang JC, Evans CP, Corey E, Chen HW, Yu A, Ghosh PM, Gao AC. Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes. Commun Med (Lond). 2022 Sep 21;2:118. doi:10.1038/s43856-022-00182-9. PMID:36159187.

Batra N, Kumar VE, Nambiar R, De Souza C, Yuen A, Le U, Verma R, Ghosh PM, Vinall RL. Exploring the therapeutic potential of Neem (Azadirachta Indica) for the treatment of prostate cancer: a literature review. Ann Transl Med. 2022 Jul;10(13):754. doi:10.21037/atm-22-94. PMID:35957716.

Dutta S, Polavaram NS, Islam R, Bhattacharya S, Bodas S, Mayr T, Roy S, Albala SAY, Toma MI, Darehshouri A, Borkowetz A, Conrad S, Fuessel S, Wirth M, Baretton GB, Hofbauer LC, Ghosh P, Pienta KJ, Klinkebiel DL, Batra SK, Muders MH, Datta K. Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer. Oncogene. 2022 Jul;41(30):3747-3760. doi:10.1038/s41388-022-02382-y. Epub 2022 Jun 27. PMID:35754042.

Tsamouri MM, Durbin-Johnson BP, Culp WTN, Palm CA, Parikh M, Kent MS, Ghosh PM. Untargeted Metabolomics Identify a Panel of Urinary Biomarkers for the Diagnosis of Urothelial Carcinoma of the Bladder, as Compared to Urolithiasis with or without Urinary Tract Infection in Dogs. Metabolites. 2022 Feb 24;12(3):200. doi:10.3390/metabo12030200. PMID:35323643.

Tsamouri MM, Steele TM, Mudryj M, Kent MS, Ghosh PM. Comparative Cancer Cell Signaling in Muscle-Invasive Urothelial Carcinoma of the Bladder in Dogs and Humans. Biomedicines. 2021 Oct 14;9(10):1472. doi:10.3390/biomedicines9101472. PMID:34680588.

Steele T, Sam A, Evans S, Browning E, Krig S, Macias K, Konda A, Siddiqui S, Durbin-Johnson B, Ghosh P, Vinall R. Androgen Receptor-Mediated Nuclear Transport of NRDP1 in Prostate Cancer Cells Is Associated with Worse Patient Outcomes. Cancers (Basel). 2021 Sep 2;13(17):4425. doi:10.3390/cancers13174425. PMID:34503235.

Katleba K, Lombard AP, Tsamouri MM, Baek HB, Nishida KS, Libertini SJ, Platero AJ, Ma AH, Pan CX, Ghosh PM, Mudryj M. Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis. Cancer Lett. 2021 Apr 28;504:49-57. doi:10.1016/j.canlet.2021.01.029. Epub 2021 Feb 4. PMID:33549708.

Messner EA, Steele TM, Tsamouri MM, Hejazi N, Gao AC, Mudryj M, Ghosh PM. The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy. Biomedicines. 2020 Oct 15;8(10):422. doi:10.3390/biomedicines8100422. PMID:33076388.